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The National Institute for Health Research 
(NIHR) HTA program, which undertakes 
independent HTA in the UK, also recog-
nizes the role of patients and public. They 
have taken a decision to actively involve 
patients in their work program. They state 
that: «HTA research must address the ques-
tions that are important to those who use 
NHS services, and to ensure that it does this 
the HTA program actively involves mem-
bers of the public throughout the research 
process» [5].
There is evidence that involvement is also 
considered important across the HTA field. 
Over half of the members of the International 
Network of Agencies for Health Technology 
Assessment (INAHTA) who responded when 
surveyed in 2005, said they involve consum-
ers in their HTA work. Further, 83% said that 
they intended to involve them in the future 
[6]. Bridges and Jones suggest that patients 
are the most important stakeholder amongst 
many in HTA [7].
However, there remains concern that pa-
tients’ perspective are rarely included, per-
haps because they are seen as anecdotal, bi-
ased views [3].
HOW CAN YOU INVOLVE THE 
PUBLIC AND PATIENTS IN HTA?
The options for involvement are many and 
varied, and that provides a menu of options 
for those undertaking HTA to develop an 
approach that works in their specific con-
text.
Facey et al. highlight that there are a number 
of research approaches [3]:
 - systematic reviews of qualitative re-
search;
 - primary research including:
 - qualitative methods such as individual 
in-depth interviews and focus groups
 - quantitative methods such as surveys; 
including tools such as the EQ 5D.
Using NICE as a practical example, NICE 
provides a range of options including [8]:
 - Allowing the public and patients to make 
suggestions for topic areas. This helps to 
involve the public and patients when not 
INTRODUCTION
Health Technology Assessment (HTA) is 
defined as «a multidisciplinary process that 
summarizes information about the medical, 
social, economic and ethical issues related to 
the use of a health technology in a systematic, 
transparent, unbiased, robust manner. Its aim 
is to inform the formulation of safe, effec-
tive, health policies that are patient focused 
and seek to achieve best value» [1]. And to 
really be that in practice, patients need to be 
involved, not least to respond to the need for 
HTA to be patient-focused as outlined in the 
above definition.
The findings that result from appraisal can be 
very influential in either providing patient ac-
cess to a new technology or limiting access. 
The approach that countries take to HTA var-
ies. This editorial draws on selected literature 
and the example of the National Institute 
for Health and Clinical Excellence (NICE) 
in England to explore why patients, and the 
public more generally, should be involved 
and how that can be achieved in theory and 
practice.
WHY INVOLVE THE PUBLIC 
AND PATIENTS IN HTA?
There are a number of reasons why the public 
and patients should be involved in HTA.
As NICE acknowledges in their work, pa-
tients can [2]:
 - provide a unique source of evidence on 
the personal impact of a disease and how 
technology can make a difference;
 - identify shortcomings in the published 
research.
Involvement of patients also supports a more 
transparent approach, making more explicit 
the normative judgments made in assessing a 
technology [3].
NICE also acknowledges that given their de-
cisions affect the allocation of public funds, 
often towards certain groups of patients and 
given limited funds, away from other groups 
of patients (or potential patients in the fu-
ture), that the public more broadly needs rep-
resentation [4].
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all technologies can be assessed and sub-
ject to full appraisal.
 - Inviting responses to the development of 
NICE guidance (all the way from scop-
ing, draft, to final guidance). This pro-
vides a number of opportunities as work 
progresses for the public and patients to 
comment across the key stages of HTA. 
This includes commenting on the inter-
pretation of the evidence on both costs 
and benefits of treatment as NICE re-
views the evidence and conducts it’s de-
liberations.
 - Inviting public and patient members on to 
Working Groups.
 - Including public and patient members on 
NICE Appraisal Committees (ACs). ACs 
made recommendations to the NHS on 
the use of technologies. There are 12 lay 
members of the 30-33 total members in 
each of the four committees, who have a 
tenure of 3 years with the possibility of 
extending to 10 years.
 - Including public and patient members on 
the Partners Council (PC). The PC re-
views NICE’s annual report and provides 
a forum for exchange of ideas, concepts 
and future plans. There are 49 places, 
with patient/public representatives ac-
counting for 6 places.
 - Inviting the public to be part of the Citi-
zens Council. Thirty members of the pub-
lic come together to debate questions set 
by NICE to provide guidance that under-
pins NICE Appraisal Committee recom-
mendations. Members have a tenure of 
3 years, and 10 members change every 
year.
 - Inviting the public and patients to con-
tribute to the NICE database on imple-
mentation.
This means that the public and patients have 
numerous ways to be involved, which offer 
lesser or greater commitment for individu-
als and organizations. The relative success of 
each approach has not to the knowledge of 
the author been considered.
WHAT HAPPENS WHEN 
YOU INVOLVE THE PUBLIC 
AND PATIENTS?
Final decisions made as a result of HTA are 
the result of a complex set of factors (i.e. the 
clinical and economic evidence) and delibera-
tions. In addition, “stakeholder persuasion” 
has been identified as a factor in NICE recom-
mendations [9]. Disentangling the impact of 
each factor is difficult, however there is evi-
dence that patient organization submissions 
can increase the likelihood of a routine rather 
than restricted use recommendation [10].
MORE NEEDS TO BE DONE
Few studies are known to the author about 
the approach to involvement the public and 
patients in HTA. However, those studies that 
are available suggest that there may be good-
will to those patients who took part in de-
veloping clinical guidelines with NICE, but 
their perception of influence they had versus 
others (such as health professionals, health 
economists and the pharmaceutical industry) 
was limited [11]. There is also a need to sup-
port patient representatives and provide train-
ing and information [12].
Overall, more needs to be done to deliver on 
the potential of involvement with the public 
and patients [8]. In the authors’ view the first 
step is to ensure that there is a recognition of 
both the legitimate role for public and patients 
and the value that they can bring to decision 
making, and the next to explore what the prac-
tical options may be for involvement. Given 
the myriad number of ways HTA is applied in 
practice, this should start with a look at the 
main options in use in other countries, such as 
the NICE example above, and then to apply 
judgment as to what is appropriate in the spe-
cific context. Lastly there should be ongoing 
evaluation and adaption to ensure that public 
and patient involvement is effective and cost-
effective. This will provide a rich source of in-
sights to adapt and learn over time, to ensure 
that HTA is truly public and patient-focused.
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